IRIS
MIKULSKA, MALGORZATA KAROLINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 18.833
AS - Asia 199
SA - Sud America 45
NA - Nord America 3
AF - Africa 1
Totale 19.081
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 18.832
CN - Cina 144
BR - Brasile 37
VN - Vietnam 28
SG - Singapore 20
AR - Argentina 3
US - Stati Uniti d'America 3
CO - Colombia 2
EC - Ecuador 2
KZ - Kazakistan 2
AT - Austria 1
BD - Bangladesh 1
IN - India 1
IQ - Iraq 1
NP - Nepal 1
PY - Paraguay 1
SY - Repubblica araba siriana 1
TN - Tunisia 1
Totale 19.081
Salva come PNG Salva come JPEG
Città #
Genova 8.772
Genoa 6.646
Vado Ligure 1.721
Rapallo 1.605
Bordighera 77
Beijing 63
Ho Chi Minh City 13
Singapore 9
Hanoi 5
Verona 4
Pisa 3
São Paulo 3
Ashburn 2
Curitiba 2
Haiphong 2
Hải Dương 2
Milan 2
Treviglio 2
Várzea Paulista 2
Almaty 1
Ambato 1
Anápolis 1
Astana 1
Baghdad 1
Barra do Piraí 1
Biên Hòa 1
Boydton 1
Brasília 1
Cachoeiro de Itapemirim 1
Campos dos Goytacazes 1
Carapicuíba 1
Chapai Nawabganj 1
Córdoba 1
Damascus 1
Divino 1
Divinópolis 1
El Carmen de Bolívar 1
Getúlio Vargas 1
Goianira 1
Gravataí 1
Guararema 1
Guarulhos 1
Guaíba 1
Ha Long 1
Ipojuca 1
Itabaiana 1
Joinville 1
Lucknow 1
Luque 1
Macapá 1
Maceió 1
Monte Alto 1
Palhoça 1
Phủ Lý 1
Piraju 1
Porto Alegre 1
Quito 1
Quận Chín 1
Reconquista 1
San Lorenzo 1
Santos 1
Serra 1
Socorro 1
Sousse 1
São Vicente 1
Teresina 1
Thái Bình 1
Thái Nguyên 1
Tuparendi 1
Vienna 1
Totale 18.986
Salva come PNG Salva come JPEG
Nome #
Clinical characteristics, management and in-hospital mortality of patients with COVID-19 In Genoa, Italy 262
Bench-to-bedside review: therapeutic management of invasive candidiasis in the intensive care unit 203
Initial serum (1,3)-β-d-glucan as a predictor of mortality in proven candidaemia: findings from a retrospective study in two teaching hospitals in Italy and Brazil 199
Primary prophylaxis of invasive fungal diseases in allogeneic stem cell transplantation: revised recommendations from a consensus process by Gruppo Italiano Trapianto Midollo Osseo (GITMO). 195
Case report: management and HBV sequencing in a patient co-infected with HBV and HIV failing tenofovir. 185
Use of Cefiderocol in Adult Patients: Descriptive Analysis from a Prospective, Multicenter, Cohort Study 181
Bacterial infections in hematopoietic stem cell transplantation recipients. 176
Effectiveness of a project to prevent HIV vertical transmission in the Republic of Congo. 164
Bronchoalveolar lavage fluid characteristics and outcomes of invasively mechanically ventilated patients with COVID-19 pneumonia in Genoa, Italy 160
Use of colistin in adult patients: a cross-sectional study 158
Non-cultural methods for the diagnosis of invasive fungal disease 157
Prevalence and prognostic value of cardiac troponin in elderly patients hospitalized for COVID-19 155
Invasive candidiasis in non-hematological patients. 154
Biomarkers for Diagnosis and Follow-Up of Invasive Candidiasis: A Brief Review of the ECIL Recommendations 151
Hepatitis B reactivation in HBsAg-negative/HBcAb-positive allogeneic haematopoietic stem cell transplant recipients: risk factors and outcome. 151
Impact of a mixed educational and semi-restrictive antimicrobial stewardship project in a large teaching hospital in Northern Italy 151
Bacterial infections in hematopoietic stem cell transplant recipients 150
Prevalence and Clinical Significance of Persistent Viral Shedding in Hospitalized Adult Patients with SARS-CoV-2 Infection: A Prospective Observational Study 148
Pulmonary cryptococcosis with severe eosinophilia in an immunocompetent patient. 147
European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. 147
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an Infectious Diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52) 147
Invasive pulmonary aspergillosis in intensive care units: is it a real problem? 146
Desirability of outcome ranking (DOOR) for comparing diagnostic tools and early therapeutic choices in patients with suspected candidemia 146
Performance of serum (1,3)-ß-d-glucan screening for the diagnosis of invasive aspergillosis in neutropenic patients with haematological malignancies 146
Pathogens in Severe Sepsis: New Paradigms for Fungi Treatment 146
Invasive mycoses in children receiving hemopoietic SCT 143
Lower sensitivity of serum (1,3)-β-D-glucan for the diagnosis of candidaemia due to Candida parapsilosis 142
(1-3)-β-d-glucan in cerebrospinal fluid is useful for the diagnosis of central nervous system fungal infections. 142
Bloodstream infections in critically ill patients with COVID-19 142
Blood stream infections in allogeneic hematopoietic stem cell transplant recipients: reemergence of Gram-negative rods and increasing antibiotic resistance. 141
Bloodstream infections in neutropenic cancer patients: A practical update 141
De-Escalation and Discontinuation of Empirical Antibiotic Treatment in a Cohort of Allogeneic Hematopoietic Stem Cell Transplantation Recipients during the Pre-Engraftment Period 141
Efficacy of lamivudine prophylaxis in preventing hepatitis B virus reactivation in patients with resolved infection undergoing allogeneic SCT and receiving rituximab 141
Will new antimicrobials overcome resistance among Gram-negatives? 140
Multidrug-resistant bacteria in hematology patients: Emerging threats 140
Galactomannan: testing the same sample twice? 138
Risk factors for severe complications of the novel influenza A (H1N1): analysis of patients hospitalized in Italy. 136
Occurrence, presentation and treatment of candidemia. 135
Pre-Engraftment Bloodstream Infections after Allogeneic Hematopoietic Cell Transplantation: Impact of T Cell-Replete Transplantation from a Haploidentical Donor 135
Clinical characteristics, management and in-hospital mortality of patients with coronavirus disease 2019 in Genoa, Italy 135
Mortality after bloodstream infections in allogeneichaematopoietic stem cell transplant (HSCT) recipients 134
Aetiology and resistance in bacteraemias among adult and paediatric haematology and cancer patients. 134
Voriconazole in clinical practice. 131
Piperacillin/tazobactam (TazocinTM) seems to be no longer responsible forfalse-positive results of the galactomannan assay 130
Epidemiology of viral respiratory tract infections in an outpatient haematology facility 129
Screening With Serum Galactomannan Might Be Associated With Better Outcome Than Symptom-Triggered Galactomannan Testing in Allogeneic HSCT Recipients With Invasive Aspergillosis. 127
The Beta-d-glucan Test: Time to Re-Visit Its Utility in IFI Diagnosis 127
Clinical performance of the (1,3)-β-D-glucan assay in early diagnosis of nosocomial Candida bloodstream infections. 127
Candida auris Candidemia in Critically Ill, Colonized Patients: Cumulative Incidence and Risk Factors 127
ECILrecommendations for the use of biological markers for the diagnosis of invasivefungal diseases in leukemic patients and hematopoietic SCT recipients 126
Serum sickness (Like Reaction) in a patient treated with alemtuzumab for multiple sclerosis: A case report 125
Correction to: Impact of a mixed educational and semi-restrictive antimicrobial stewardship project in a large teaching hospital in Northern Italy (Infection, 10.1007/s15010-017-1063-7) 123
External validation of unsupervised COVID-19 clinical phenotypes and their prognostic impact 122
SIMIFF study: Italian fungal registry of mold infections in hematological and non-hematological patients. 122
Galactomannan testing might be useful for early diagnosis of fusariosis. 122
Combined use of serum (1,3)-β-d-glucan and procalcitonin for the early differential diagnosis between candidaemia and bacteraemia in intensive care units 122
CMV infection after transplant from cord blood compared to other alternative donors: the importance of donor-negative CMV serostatus. 122
Efficacy of daptomycin lock therapy in the treatment of bloodstream infections related to long-term catheter. 121
Current and emerging pharmacotherapy for the treatment of infections following open-heart surgery 121
Outbreak of Ralstonia pickettii bacteraemia in patients with haematological malignancies and haematopoietic stem cell transplant recipients 120
Current research in empirical therapy for febrile neutropenia in cancer patients: what should be necessary and what is going on. 120
Visceral leishmaniasis in hematopoietic cell transplantation: Case report and review of the literature 120
2017 ECIL 7 vaccine guidelines 120
Diagnostic and therapeutic approach to infectious diseases in solid organ transplant recipients 118
The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European Conference on Infections in Leukemia. 117
La Definizione di Aspergillosi 117
Extensive activation, tissue trafficking, turnover and functional impairment of NK cells in COVID-19 patients at disease onset associates with subsequent disease severity 117
Enterococcal bloodstream infection after hematopoietic stem cell transplant: experience of a center with a low prevalence of vancomycin-resistant enterococci. 116
Tocilizumab and steroid treatment in patients with COVID-19 pneumonia 116
Pneumocystis jirovecii pneumonia in intensive care units: a multicenter study by ESGCIP and EFISG 115
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4) 114
Ocrelizumab does not impair B- and T-cell responses to primary VZV infection in a patient with MS 114
Discontinuation of empirical antibiotic therapy in neutropenic leukaemia patients with fever of unknown origin is ethical 114
Risk factors for enterococcal bacteremia in allogeneic hematopoietic stem cell transplant recipients. 113
Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011). 113
Management of chronic viral hepatitis in the hematological patient 113
Invasive aspergillosis: diagnosis, prophylaxis and treatment 112
Comparable survival using a CMV-matched or a mismatched donor for CMV+ patients undergoing T-replete haplo-HSCT with PT-Cy for acute leukemia: a study of behalf of the infectious diseases and acute leukemia working parties of the EBMT 112
Vaccination of patients with haematological malignancies who did not have transplantations: guidelines from the 2017 European Conference on Infections in Leukaemia (ECIL 7) 112
European survey on principles of prudent antibiotic prescribing teaching in undergraduate students 108
Evaluation of mass spectrometry-based detection of panfungal serum disaccharide for diagnosis of invasive fungal infections: Results from a collaborative study involving six European clinical centers 108
Current role of echinocandins in the management ofinvasive aspergillosis 107
Antimicrobial Resistance in Gram-Negative Rods Causing Bacteremia in Hematopoietic Stem Cell Transplant Recipients: Intercontinental Prospective Study of the Infectious Diseases Working Party of the European Bone Marrow Transplantation Group 106
Fluoroquinolone prophylaxis during neutropenia: what can we expect nowadays? 105
Aggressive multiple sclerosis: a single-centre, real-world treatment experience with autologous haematopoietic stem cell transplantation and alemtuzumab 105
Manuale per la gestione delle complicanze infettive nell’emato-oncologia e trapianto di midollo osseo 104
null 102
No report on Zika virus infection in EBMT registry: Infectious Diseases Working Party statement 102
Protective environment for hematopoietic cell transplant (HSCT) recipients: The Infectious Diseases Working Party EBMT analysis of global recommendations on health-care facilities 102
Why is community-associated MRSA spreading across the world and how will it change clinical practice? 101
New treatment options against gram-negative organisms. 100
Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7) 100
A Response to: Letter to the Editor Regarding Management of Adult Patients with COVID-19 Outside Intensive Care Units: Guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP) 100
Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines 99
Impact of antibiotic resistance on outcomes of neutropenic cancer patients with Pseudomonas aeruginosa bacteraemia (IRONIC study): Study protocol of a retrospective multicentre international study 99
ECIL guidelines for the prevention, diagnosis and treatment of BK polyomavirus-associated haemorrhagic cystitis in haematopoietic stem cell transplant recipients 98
Serial monitoring of isavuconazole blood levels during prolonged antifungal therapy 98
ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients 97
Risk factors for invasive aspergillosis and related mortality in recipients of allogeneic SCT from alternative donors: an analysis of 306 patients 96
Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation—a position paper 94
Totale 13.053
Salva come PNG Salva come JPEG
Categoria #
all - tutte 75.807
article - articoli 73.560
book - libri 325
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 1.922
Totale 151.614
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.119 0 0 0 0 87 81 185 198 133 187 122 126
2021/20221.741 67 48 101 233 75 168 77 414 86 179 70 223
2022/20232.076 194 139 27 181 263 285 72 138 303 132 278 64
2023/20241.477 81 168 55 189 158 217 83 107 71 47 119 182
2024/20254.357 100 324 107 304 595 426 414 733 212 219 453 470
2025/20262.595 943 307 626 706 13 0 0 0 0 0 0 0
Totale 19.570